Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets genes by binding to the 3′-untranslated regions. They play vital roles in diverse biological processes, including the development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial role in the HF pathological process. MiRNAs involved in various biological process, such as differentiation, apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use in HF treatment.
Keywords: Non-coding RNA, microRNAs, hepatic fibrosis, hepatic stellate cells, biomarkers, therapy.
Current Pharmaceutical Design
Title:Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update
Volume: 27 Issue: 27
Author(s): Sai Zhu , Xin Chen, Yu Chen, Xiao-Feng Li, Si-Yu Chen, Juan-Juan Li , Ao Wang, Cheng Huang*Jun Li *
Affiliation:
- Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui,China
- Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui,China
Keywords: Non-coding RNA, microRNAs, hepatic fibrosis, hepatic stellate cells, biomarkers, therapy.
Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets genes by binding to the 3′-untranslated regions. They play vital roles in diverse biological processes, including the development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial role in the HF pathological process. MiRNAs involved in various biological process, such as differentiation, apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use in HF treatment.
Export Options
About this article
Cite this article as:
Zhu Sai , Chen Xin , Chen Yu , Li Xiao-Feng , Chen Si-Yu , Li Juan-Juan , Wang Ao , Huang Cheng*, Li Jun *, Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update, Current Pharmaceutical Design 2021; 27 (27) . https://dx.doi.org/10.2174/1381612826666201023143542
DOI https://dx.doi.org/10.2174/1381612826666201023143542 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design HSP60 as a Drug Target
Current Pharmaceutical Design Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry LSINCT5: A Novel lncRNA in Cancers
Current Medicinal Chemistry Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design